Vor Dividend Paid And Capex Coverage Ratio from 2010 to 2025
| VOR Stock | USD 0.85 0.02 1.92% |
Dividend Paid And Capex Coverage Ratio | First Reported 2010-12-31 | Previous Quarter (435.20) | Current Value (413.44) | Quarterly Volatility 140.05929661 |
Check Vor Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vor Biopharma's main balance sheet or income statement drivers, such as Net Interest Income of 4.5 M, Interest Income of 4.5 M or Depreciation And Amortization of 3.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.75. Vor financial statements analysis is a perfect complement when working with Vor Biopharma Valuation or Volatility modules.
Vor | Dividend Paid And Capex Coverage Ratio |
Latest Vor Biopharma's Dividend Paid And Capex Coverage Ratio Growth Pattern
Below is the plot of the Dividend Paid And Capex Coverage Ratio of Vor Biopharma over the last few years. It is Vor Biopharma's Dividend Paid And Capex Coverage Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vor Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Dividend Paid And Capex Coverage Ratio | 10 Years Trend |
|
Dividend Paid And Capex Coverage Ratio |
| Timeline |
Vor Dividend Paid And Capex Coverage Ratio Regression Statistics
| Arithmetic Mean | (69.42) | |
| Geometric Mean | 22.44 | |
| Coefficient Of Variation | (201.75) | |
| Mean Deviation | 91.77 | |
| Median | (13.18) | |
| Standard Deviation | 140.06 | |
| Sample Variance | 19,617 | |
| Range | 426 | |
| R-Value | (0.62) | |
| Mean Square Error | 12,995 | |
| R-Squared | 0.38 | |
| Significance | 0.01 | |
| Slope | (18.18) | |
| Total Sum of Squares | 294,249 |
Vor Dividend Paid And Capex Coverage Ratio History
About Vor Biopharma Financial Statements
Vor Biopharma shareholders use historical fundamental indicators, such as Dividend Paid And Capex Coverage Ratio, to determine how well the company is positioned to perform in the future. Although Vor Biopharma investors may analyze each financial statement separately, they are all interrelated. The changes in Vor Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Vor Biopharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Dividend Paid And Capex Coverage Ratio | (435.20) | (413.44) |
Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.